Oncology

Roche attributes a $3.83 billion reduction in sales to biosimilar competition.

Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.

Amgen's 2020 biosimilar report goes into detail on market share and costs for biosimilars across the therapeutic spectrum in the United States.

Years ahead of patent expirations for programmed death-1 (PD-1) inhibitors, biosimilar companies have begun focusing on these targeted drugs.

Sometimes the reference product exhibits pricing resistance against the competitive effect of biosimilars, according to a Pharmaceutical Strategies Group report.

As the United States continues to struggle to increase biosimilar uptake, presenters at the DIA 2020 Biosimilars Conference offered insight into what other countries have done to encourage biosimilar use.

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.

During the coronavirus disease 2019 (COVID-19) pandemic, patients are more likely to have delayed cancer screenings rather than their doctors and clinics.

Centus’ Equidacent became Europe’s fourth bevacizumab biosimilar to receive marketing authorization.

California has become the first state to implement a policy to produce and distribute its own drug products to help lower costs.

Germany could eke out more gains from biosimilars on top of its already impressive savings, investigators write.

Trial results demonstrated that Innovent Biologics’ bevacizumab biosimilar was effective in combination therapy with a PD-1 inhibitor in patients with hepatocellular carcinoma.

Some acts by companies in the biologics marketplace may go too far in preventing free market activity, according to Markus H. Meier, acting director for the Federal Trade Commission (FTC) Bureau of Competition.

A secretive biosimilars company notches yet another co-licensing deal but withholds full details.

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Biosimilars from Samsung Bioepis have demonstrated equivalency in clinical trial and real world settings, according to 2 prominent cancer specialists.

Breast cancer specialist Hope S. Rugo, MD, FASCO, an advisory board member for The Center for Biosimilars®, has been at the forefront of groundbreaking oncology advancements.

Lotus and CKD Pharmaceutical intend to be among the first to bring a darbepoetin alpha biosimilar to Southeast Asia.

Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.

Singapore-based PrestigePharma presents fresh equivalency data supporting its case for regulatory approval of HD201.

The American College of Physicians (ACP) said many reforms are needed to install appropriate checks and balances in the biologic drugs marketplace.

Courts have allowed biosimilar developers "safe harbor" against infringement suits, but there are limits, attorneys from Goodwin Proctor explain.

This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.

Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.

Some European markets are more formidable than others with regard to complexity and getting biosimilars established, but there are good places to start, Jonathan Sweeting, head of Europe for Samsung Bioepis, explains.

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

The Australia-based biosimilar company hopes to compete with blockbuster programmed death-1 (PD-1) inhibitor franchises owned by Merck and Bristol Myers Squibb.

A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).

Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.

With the launch of an adalimumab, Cadila hopes to get a piece of the worldwide biosimilar market for antirheumatic treatments.